Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Allergy & Immunology
•
Mast Cell Disorders
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Does a patient with known systemic mastocytosis need a bone biopsy of lytic vertebral lesions to rule out other etiologies?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Do you perform genetic testing when patients have persistent hypogammaglobulinemia after rituximab therapy?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
